Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 16.90
-0.18 (-1.05%)
Aug 14, 2026, 5:00 PM CET
Ryvu Therapeutics Financials Overview
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 88.38 | 87.7 | 101.96 | 67.3 | 68.44 | 35.41 |
Revenue Growth | 92.83% | -13.98% | 51.51% | -1.67% | 93.25% | -4.16% |
Gross Profit Gross Profit Growth | 73.16 | 72.9 | 82.38 | 49.74 | 51.03 | 21.69 |
Operating Income Operating Income Growth | -81.86 | -97.21 | -121.97 | -97.38 | -69.49 | -78.89 |
Net Income Net Income Growth | -88.6 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Earnings Per Share EPS Growth | -3.84 | -4.38 | -4.82 | -4.02 | -4.56 | -4.31 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Poland Poland Growth | 0.08 | 0.06 | 0.04 | 0.11 | 0.16 |
EU Members EU Members Growth | 61.6 | 69.33 | 41.66 | 24.62 | 11.03 |
Other Countries Other Countries Growth | 0.57 | 8.59 | 5.16 | 14.23 | - |
Total Total Growth | 62.25 | 77.97 | 46.86 | 38.95 | 11.19 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 83.11 | 107.68 | 225.93 | 233.67 | 102.45 | 88.23 |
Total Debt Total Debt Growth | 96.03 | 95.9 | 102.12 | 9.76 | 12.67 | 13.19 |
Net Cash (Debt) Net Cash Growth | -12.93 | 11.78 | 123.81 | 223.91 | 89.77 | 75.04 |
Net Cash Growth | - | -90.49% | -44.71% | 149.42% | 19.63% | -51.20% |
Net Cash Per Share Net Cash Per Share Growth | -0.56 | 0.51 | 5.36 | 9.78 | 4.89 | 4.09 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -92.76 | -114.1 | -129.48 | -84.55 | 21.32 | -58.89 |
Capital Expenditures CapEx Growth | -7.41 | -7.47 | -5.9 | -8.58 | -6.25 | -11.98 |
Free Cash Flow Free Cash Flow Growth | -100.17 | -121.57 | -135.38 | -93.13 | 15.07 | -70.87 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 82.77% | 83.12% | 80.80% | 73.91% | 74.57% | 61.24% |
Operating Margin | -92.63% | -110.84% | -119.63% | -144.70% | -101.54% | -222.76% |
Pretax Margin | -99.96% | -115.32% | -109.00% | -136.88% | -115.72% | -222.97% |
Profit Margin | -100.25% | -115.42% | -109.29% | -136.88% | -122.42% | -223.30% |
FCF Margin | -113.34% | -138.62% | -132.78% | -138.39% | 22.01% | -200.12% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 163.70 | 163.70 | 163.70 | 163.70 | 163.70 |
P/FCF Ratio | - | - | - | - | 75.58 | - |
PS Ratio | 4.42 | 7.14 | 8.73 | 19.76 | 16.64 | 31.62 |